NTS Plus, Affitech amend R&D, licensing agreement

With this amendment the rights and obligations under the R&D and licensing agreement will be transferred from NTS Plus to the newly established Russian biotech company International Biotech Center Generium (IBC Generium).

IBC Generium is controlled by Affitech chairman Aleksandr Shuster and Victor Kharitonin, who through TransNova Investments are majority shareholders in Affitech.

Affitech is a publicly human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway.

The company uses a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas.

CBAS (Cell Based Antibody Selection) is Affitech’s discovery engine for the isolation of lead antibodies to cell surface molecules.

Affitech co-develops its two lead antibody drug candidates AT001/r84 and AT008/CCR4 with Russian partner IBC Generium.